This reports provides a data-driven overview of the current and future competitive landscape in FSD therapeutics.
Components of the report include -
- More than 384,000,000 total prevalent cases of FSD were there in 2023 in the 16 countries covered in the publisher's epidemiology forecast for FSD.
- Marketed drugs for FSD are widely genericized and the majority of drugs indicated to treat FSD are estrogen receptor agonist.
- Out of 24 drugs in the pipeline for FSD, only three are in the Phase III stage of development.
- Approximately 51% of the clinical trials initiated over the last 10 years for FSD have been conducted in sites across North America, followed by 21% in Europe.
- In deals involving companies developing FSD assets that occurred during past 10 years, asset transaction was the most prevalent deal type Globally.
Scope
The publisher's FSD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the FSD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global FSD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Preface
3 Disease Landscape
4 Marketed Drugs Assessment
5 Pricing and Reimbursement Assessment
6 Pipeline Drugs Assessment
7 Clinical Trials Assessment
8 Deals Landscape
9 Commercial Assessment
11 Appendix
